- PetVivo Holdings, Inc. has entered into an **exclusive 10-year white-label licensing agreement** with Digital Landia Holding Corp for its **Agentic Pet AI technology**, targeting the veterinary market.  **[1512922_a68d79c6d9c149c4bb855b91e4b7bec1_0]** **[1512922_a68d79c6d9c149c4bb855b91e4b7bec1_1]** 
- This technology aims to reduce veterinary client acquisition costs by **90% - 98%** (from $50-$150+ to **$1.50-$5.00** per targeted outreach) and capture the **rapidly growing Gen Z pet parent demographic**.  **[1512922_a68d79c6d9c149c4bb855b91e4b7bec1_0]** 
- The dual-platform, which includes **9 specialized AI diagnostic agents**, is scheduled for launch in **Q1 2026**.  **[1512922_a68d79c6d9c149c4bb855b91e4b7bec1_1]** 
- PetVivo will utilize this agreement to enter the **$4.9 billion US veterinary AI market**, with access to **30,000+ addressable clinics** and existing relationships with **1,000+ veterinary clinics**.  **[1512922_a68d79c6d9c149c4bb855b91e4b7bec1_1]**

PetVivo Holdings Licenses Agentic Pet AI Technology

- **PetVivo Animal Health, Inc.**, a subsidiary of PetVivo Holdings, Inc., has entered into a **Vendor Partner Agreement** with **Veterinary Growth Partners (VGP)**.  **[1512922_702f7483d7f940f4b962c95816d0ceeb_0]** 
- Under this agreement, VGP will actively promote PetVivo's key products, **Spryng® with OsteoCushion® Technology and PrecisePRP®**, to its network of **over 7,300 veterinary members** across the United States.  **[1512922_702f7483d7f940f4b962c95816d0ceeb_0]** 
- This collaboration aims to **expand national availability, accelerate product adoption, and enhance purchasing efficiency** for veterinary practices seeking non-pharmaceutical and regenerative solutions.  **[1512922_702f7483d7f940f4b962c95816d0ceeb_1]** 
- **Spryng** is an intra-articular injectable veterinary medical device for managing joint-related conditions, while **PrecisePRP** is a first-in-class, off-the-shelf platelet-rich plasma product designed for use by veterinarians.  **[1512922_702f7483d7f940f4b962c95816d0ceeb_0]**

PetVivo Animal Health, Inc. Enters Vendor Partner Agreement with Veterinary Growth Partners

- PetVivo Holdings, Inc. entered into note conversion agreements to convert **fourteen promissory notes** with an aggregate outstanding debt of **$2,018,155**.  **[1512922_f425b558b64c447c9e128943e455cd36_0]** 
- This debt, consisting of **$1,850,000** in principal and **$168,155** in accrued interest, was converted into **3,669,806 shares** of common stock.  **[1512922_f425b558b64c447c9e128943e455cd36_0]** 
- The effective conversion prices for the notes ranged from **$0.50 to $0.75 per share**.  **[1512922_f425b558b64c447c9e128943e455cd36_0]** 
- This action **eliminates over $2 million of Company debt** from the balance sheet, strengthening PetVivo's financial position and allowing more resources for the commercialization of its products, **SPRYNG® with OsteoCushion® Technology** and **Precise PRP®**.  **[1512922_f425b558b64c447c9e128943e455cd36_0]** **[1512922_f425b558b64c447c9e128943e455cd36_1]**

PetVivo Holdings (PETV)